Polyneuron raises $22.6M series A to bring neuropathy therapy into clinic

Backed by Sofinnova Partners and New Enterprise Associates, Polyneuron raised CHF22.5M ($22.6 million) in a series A round to bring its anti-MAG neuropathy therapy, PN-1007, into the clinic.

Polyneuron Pharmaceuticals AG (Basel, Switzerland) is developing glycopolymers that act as decoys for the autoantibodies that drive autoimmune diseases, such as anti-MAG neuropathy, and are designed to be more effective and safer than other therapies (see "Catching Antibodies with Polymers"). ...